NEW YORK -- (Business Wire)
Levi & Korsinsky announces it has commenced an investigation of Synergy
Pharmaceuticals Inc. (NASDAQ: SGYP) concerning possible violations of
federal securities laws.
On September 5, 2017, Synergy issued a press release announcing it had
closed on a “non-dilutive” $300 million loan from CRG Partners III L.P.,
which would be available to Synergy “when needed” and fund the Company’s
operations through 2019. On November 14, 2017, Synergy revealed that
terms of the loan agreement, omitted from prior statements regarding the
loan, prevented it from accessing $200 million of the loan without
conducting a dilutive secondary offering or offerings of shares to raise
cash and, as such, the Company was conducting a secondary offering of
its shares. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York,
California, Connecticut and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180213005313/en/
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Source: Levi & Korsinsky, LLP
© 2018 Canjex Publishing Ltd. All rights reserved.